KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Quest Diagnostics (DGX) EBT (2016 - 2026)

Quest Diagnostics' EBT history spans 18 years, with the latest figure at $334.0 million for Q1 2026.

  • On a quarterly basis, EBT rose 21.01% to $334.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.4 billion, a 16.12% increase, with the full-year FY2025 number at $1.3 billion, up 12.17% from a year prior.
  • EBT hit $334.0 million in Q1 2026 for Quest Diagnostics, up from $330.0 million in the prior quarter.
  • Over the last five years, EBT for DGX hit a ceiling of $452.0 million in Q1 2022 and a floor of $109.0 million in Q4 2022.
  • Historically, EBT has averaged $305.4 million across 5 years, with a median of $314.0 million in 2024.
  • Biggest five-year swings in EBT: crashed 78.29% in 2022 and later surged 117.43% in 2023.
  • Tracing DGX's EBT over 5 years: stood at $109.0 million in 2022, then surged by 117.43% to $237.0 million in 2023, then grew by 26.16% to $299.0 million in 2024, then rose by 10.37% to $330.0 million in 2025, then increased by 1.21% to $334.0 million in 2026.
  • Business Quant data shows EBT for DGX at $334.0 million in Q1 2026, $330.0 million in Q4 2025, and $328.0 million in Q3 2025.